AAV mediated PRPF31 gene therapy - Biogen/Massachusetts Eye and Ear
Alternative Names: PRPF31 gene therapy - Biogene/Massachusetts Eye and EarLatest Information Update: 28 Aug 2024
At a glance
- Originator Massachusetts Eye and Ear
- Developer Biogen
- Class Eye disorder therapies; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Retinal disorders